A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Last Updated May 14, 2025
Want to learn how to participate in this trial?
86974680NSC1001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 1 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
CONDITIONS
- Carcinoma, Non-Small-Cell Lung
ELIGIBILITY
Inclusion Criteria:
* Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
* Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ro
DETAILS
LOCATIONS
| Country (4) | City or Province (10) | Status |
| United States | Buffalo Roswell Park Comprehensive Cancer Center |
RECRUITING
|
| United States | New York Herbert Irving Comprehensive Cancer Center Columbia University Medical Center |
RECRUITING
|
| United States | Philadelphia Thomas Jefferson University |
RECRUITING
|
| United States | Fairfax Next Virginia |
RECRUITING
|
| Germany | Berlin Charite Research Organisation GmbH |
RECRUITING
|
| Germany | Giessen Universitaetsklinikum Giessen und Marburg GmbH |
RECRUITING
|
| South Korea | Seoul Severance Hospital Yonsei University Health System |
RECRUITING
|
| South Korea | Seoul Samsung Medical Center |
RECRUITING
|
| Spain | Barcelona Hosp. Univ. Quiron Dexeus |
RECRUITING
|
| Spain | Barcelona Hosp Univ Vall D Hebron |
RECRUITING
|
42.88645, -78.87837
40.71427, -74.00597
39.95233, -75.16379
38.84622, -77.30637
52.52437, 13.41053
50.58727, 8.67554
37.566, 126.9784
37.566, 126.9784
41.38879, 2.15899
41.38879, 2.15899
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.